Triple-negative breast cancer cells exposed to the antibody-drug conjugate sacituzumab govitecan may develop resistance to this powerful drug through alterations in both the target of the antibody and the target of the toxic payload. The findings illustrate how uncovering such mechanisms will critically inform strategies to overcome resistance to sacituzumab govitecan.
from Women's Health News -- ScienceDaily https://ift.tt/3mg7DE7
0 comments:
Post a Comment